Spatial immune heterogeneity in a mouse tumor model after immunotherapy

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Cancer immunotherapy is a growing treatment modality, but tumor immune escape limits its efficacy.
• Tumor genetic instability can drive adaptation to immune responses, leading to intratumoral immune heterogeneity.
• Understanding spatial immune heterogeneity is crucial for overcoming treatment resistance.

Purpose of the Study:

• To investigate spatial immune heterogeneity within the tumor microenvironment.
• To identify potential drivers of immune escape in a mouse model of human papillomavirus (HPV)-induced tumors after immunotherapy.
• To analyze the impact of immunotherapy on tumor cell mutations and gene expression.

Main Methods:

• Utilized a mouse model of HPV-induced tumors.
• Performed RNA sequencing for gene expression analysis.
• Conducted whole exome sequencing to identify mutations.

Main Results:

• Observed heterogeneity in immune cell infiltration, gene expression, and mutation profiles across different tumor areas.
• Found an increase in high- or moderate-impact mutations in immunotherapy-treated tumors compared to controls.
• Identified enrichment of mutated genes involved in extracellular matrix (ECM) metabolism, HPV infection, carcinogenesis, and immune processes (e.g., antigen processing, Toll-like receptor signaling).
• Immunotherapy upregulated DNA damage/repair genes (Apobec1, Apobec3) and downregulated others (homologous recombination, translesion synthesis).

Conclusions:

• The study elucidates intratumoral immune heterogeneity as a mechanism for tumor immune escape.
• Identified specific genetic and molecular alterations induced by immunotherapy that may contribute to immune evasion.
• Provides potential targets and insights for improving cancer immunotherapy strategies.